This handout is for microscopic hematuria surveillance — chronic outpatient post-workup (aua 2020 low / intermediate / high risk bands + iga / alport / sickle / anticoag / pediatric / schistosomiasis overlays). Your care team identified this based on: index aua 2020 microhematuria workup completed (cystoscopy ± ct urography) — entering surveillance phase.
Other reasons your team may use this plan: repeat ua at surveillance visit shows positive micro (3+ rbc/hpf) → reassess risk band; recurrent gross hematuria during surveillance → full re-workup required (aua 2020); iga nephropathy on prior renal biopsy → glomerular surveillance + route renal.iga-nephropathy.v1.
Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.
| Medication | Starting dose | How | When | What it does |
|---|---|---|---|---|
| Repeat UA at 6 months | — | — | — | AUA Microhematuria 2020 — if positive at 6 mo, reclassify to intermediate risk |
Plan: AUA 2020 microhematuria surveillance schedule + risk-factor modification
Contact your care team if any of the following happen:
Call 911 or go to the nearest emergency room right away if you have:
Annual review; reassess risk band q5y or with new risk factors (cigarette restart, occupational exposure change, new family hx); coordinate with primary care (AUA 2020)
Guideline: Microhematuria: AUA/SUFU Guideline (Barocas DA et al, J Urol 2020 PMID 32698717) — risk-stratified (low/intermediate/high) evaluation with cystoscopy + upper-tract imaging; microhematuria defined as ≥3 RBC/HPF on a single specimen. Schistosomiasis (praziquantel) considered in endemic-exposure hematuria.